Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera Inc (NASDAQ: NTRA) delivers cutting-edge genetic testing solutions through its proprietary molecular diagnostics platform. This news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical research breakthroughs, and regulatory milestones.
Access official press releases alongside curated analysis of NTRA's innovations in non-invasive prenatal testing, oncology diagnostics, and transplant monitoring. Our repository tracks critical updates including quarterly earnings, partnership announcements, and peer-reviewed study publications.
Key coverage areas include advancements in circulating tumor DNA detection, expansions in reproductive health screening, and financial performance metrics. Bookmark this page to monitor how Natera's bioinformatics expertise continues influencing precision medicine across 150+ countries.
Natera, Inc. (NASDAQ: NTRA) announces a study published in Gynecologic Oncology, validating its molecular residual disease (MRD) test, Signatera, for epithelial ovarian cancer (EOC). The multi-site study of 163 plasma samples from 69 patients demonstrates that Signatera outperforms CA-125 in predicting recurrence. With 100% sensitivity and specificity, it detects recurrences an average of 10 months earlier than imaging. This advancement is crucial for ovarian cancer management, which has a high recurrence rate and poor survival rates.
Natera, Inc. (NASDAQ: NTRA) announced new findings from the Trifecta study, indicating that its Prospera Kidney test, which uses donor-derived cell-free DNA (dd-cfDNA), outperforms traditional donor-specific antibody (DSA) testing in predicting antibody-mediated rejection (AMR). The study assessed 280 samples, showing dd-cfDNA metrics had AUC values of 0.84 and 0.85, significantly higher than DSA's AUC of 0.66. The results advocate for broader dd-cfDNA use in kidney transplantation for more accurate graft status assessment.
Natera, Inc. (NASDAQ: NTRA) presented new data on its Signatera™ molecular residual disease (MRD) test at the ESMO World Congress in Paris from September 9-13, 2022. Key findings include results from a large real-world study with 16,347 colorectal cancer patients, indicating that MRD-positive status significantly correlates with poorer recurrence-free survival. Signatera’s application in monitoring response to immunotherapy in early stage triple-negative breast cancer was also highlighted. The data reinforces the clinical utility of personalized MRD testing in cancer treatment decision-making.
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has announced that CEO Steve Chapman and CFO Mike Brophy will present at two upcoming investor conferences. The first is the Morgan Stanley Global Healthcare Conference on Sept. 13, 2022, at 4:05 pm ET, followed by the Baird 2022 Global Healthcare Conference on Sept. 14, 2022, at 2:00 pm ET. Live and archived webcasts will be accessible on the Natera Investor Relations website.
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has been certified by Great Place to Work® for the second consecutive year. This recognition is based on anonymous employee surveys assessing workplace culture and employee experience. CEO Steve Chapman expressed pride in the achievement, emphasizing Natera's commitment to creating a positive environment for its employees. The certification reflects employee feedback about trust and highlights Natera as one of the best companies to work for in the U.S.
Natera, Inc. (NASDAQ: NTRA) has completed full enrollment for the RenaCARE study, assessing the utility of its Renasight genetic testing panel for chronic kidney disease (CKD) patients. The study, involving over 1,700 patients across 30+ sites, aims to demonstrate how genetic testing impacts patient care in CKD. The completion of enrollment followed significant interim data analysis. A publication detailing the findings is expected in early 2023, following previous research showing that 10% of CKD cases have a genetic basis.
Natera, Inc. (NASDAQ: NTRA) announced a pre-submission to the FDA for its Panorama® non-invasive prenatal test (NIPT) at the Canaccord Genuity 42nd Annual Growth Conference. This pre-submission, filed in June 2022, addresses fetal chromosomal aneuploidies and 22q11.2 deletion syndrome. The company cited its proactive collaboration with the FDA, supported by results from the SNP-based Microdeletion and Aneuploidy Registry Trial (SMART), the largest NIPT study with over 20,000 patients. Panorama screens for severe genetic disorders as early as nine weeks into pregnancy.
Natera, Inc. (NASDAQ: NTRA) reported Q2 2022 revenues of $198.2 million, a 39.6% increase from Q2 2021. Product revenues also rose by 39.3%. Test processing surged to 499,900, up 33.0% year-over-year. The company raised 2022 revenue guidance to $805 million - $825 million. Notable achievements include securing Medicare coverage for Signatera in muscle-invasive bladder cancer and appointing a new CMO for Oncology. However, net loss reached $145.2 million or ($1.50) per share, compared to ($1.32) in 2021.
Natera, Inc. (NASDAQ: NTRA) will release its second quarter results for 2022 on August 4, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss financial results and business outlook. Natera specializes in cell-free DNA testing in oncology, women's health, and organ health, operating ISO-certified laboratories in Texas and California. Investors can register for the call to obtain dial-in details and a unique PIN.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
